LIN · Linde
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $549
Note written ·
Price against the kill line
6.2% clear of its kill line on the 17 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $549.00, set on 14 November 2026. The shares are up 7.4% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $549, which would put the shares above their July 2026 52-week high and show them leading, or a 2027 adjusted EPS outlook above the 8%–9% growth guided for 2026.
Research onlyNot in the portfolio.
Catalyst
The business · as of
Linde sells industrial gases such as oxygen, nitrogen, argon and hydrogen to manufacturers, chip makers, hospitals and refiners. Most sales come under long-term on-site and bulk supply contracts. Through Linde Engineering it also builds gas plants. Revenue was $9,404 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 29 October 2026 Linde reported third-quarter sales of $9,404 million (up 9%), raised full-year adjusted EPS guidance to $17.82–17.92, and took a $425 million charge for severance and actions at Lincare.
- What follows for the company
- Reported operating margin fell to 22.9% from 27.5% in the June quarter, and gross margin slid to 47.2%. The company plans 2026 capital spending of $5.5–6.0 billion, against $5,080 million of free cash flow over four quarters.
- What follows for its customers, suppliers and competitors
- Air Products (APD) competes for the same on-site and electronics gas projects. AdaptHealth (AHCO) faces a rival in US home oxygen, Lincare, now under strategic review.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 29 October 2026), the shares trade at a P/E of 34.5, EV/sales of 7.3 and EV/EBIT of 28.8, with a 2.1% free-cash-flow yield. That holds only if revenue keeps growing near the 9.2% of the September quarter and the operating margin returns from 22.9% toward the 27%–28% of earlier 2026 quarters.
Key figures from the filings · Materials
Quarter to 30 September 2026, filed 29 October 2026; valuation at the 17 November 2026 close
- Revenue, latest quarter ($M)
- 9,404
- Revenue, change on a year (%)
- +9.2
- Gross margin (%)
- 47.2
- Operating margin (%)
- 22.9
- Free cash flow, four quarters ($M)
- 5,080
- Net cash, cash less debt ($M)
- −22,755
- Price to earnings (×)
- 33.7
- Enterprise value to sales (×)
- 7.2
All filed numbers
What Linde reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 9,404 | +9.2 | 47.2 | 22.9 |
| first filed | 9,289 | +9.3 | 47.7 | 27.5 |
| first filed | 8,781 | +8.2 | 48.5 | 27.8 |
| first filed | 8,764 | +5.8 | 48.1 | 23.0 |
| first filed | 8,615 | +3.1 | 49.2 | 27.5 |
| first filed | 8,495 | +2.8 | 49.3 | 27.7 |
| Pre-tax income ($M) | 2,128 |
| Net income ($M) four quarters: 7,007 | 1,692 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −1.9 |
| Operating cash flow ($M) | 10,710 |
| Capital spending ($M) | 5,630 |
| Free cash flow ($M) | 5,080 |
| Cash and short-term investments ($M) | 3,947 |
| Debt ($M) | 26,702 |
| Net cash, cash less debt ($M) | −22,755 |
| Deferred revenue ($M) −3.4% on a year | 2,447 |
| Backlog, orders not yet delivered ($M) +6.5% on a year | 66,000 |
| Receivables ($M) | 5,595 |
| Inventory ($M) | 2,129 |
| Shareholders' equity ($M) | 39,422 |
| Market value ($M) | 236,479 |
| Enterprise value, market value plus net debt ($M) | 259,234 |
| Enterprise value to sales (×) | 7.2 |
| Enterprise value to operating income (×) | 28.3 |
| Price to earnings (×) | 33.7 |
| Price to book value (×) | 6.0 |
| Free-cash-flow yield (%) | 2.1 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 1.4% of shares outstanding sold short, 3.4 days of average trading to cover, +7.3% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Competitors:
- APD, AHCO
The thesis
Linde is more likely to lag than lead the S&P 500 over the next three months. The shares rose 11.3% in three months to a $526.06 close on 13 November 2026, and they trade at 34.5 times earnings, while the company's own fourth-quarter guidance slows adjusted earnings-per-share (EPS) growth to 5%–7%. The fourth-quarter report and the 2027 outlook, expected in early February 2027, settle it.
The quarter itself was solid. Linde reported third-quarter sales of $9,404 million on 29 October 2026, up 9% from a year earlier. Adjusted EPS was $4.59, up 9% and above the company's own $4.45–4.55 guide. Full-year adjusted EPS guidance moved to $17.82–17.92, from $17.70–17.90 on 31 July 2026. The price already reflects that steady compounding. The next step down in growth is in the guidance.
Two items weigh on reported results. The company took a $425 million charge in the quarter. On the 29 October 2026 call, Chief Executive Sanjiv Lamba said about half went to severance in lower-growth regions and most of the rest to actions at Lincare, the US home-care business, which is now under a strategic review. Reported EPS fell 11% to $3.66. The rating is Low because valuation, slowing guidance and a five-quarter slide in gross margin leave little room for the shares to outrun the index, even though analysts raised most targets after the report.
Bullish and bearish views on Linde plc
The bull case on Linde plc (LIN), in brief: pricing still runs ahead of costs. The bear case: growth slows in the guidance.
Bull case
- Pricing still runs ahead of costs. In the third quarter of 2026, Americas underlying sales rose 9% on 6% higher pricing and 3% higher volumes, and Asia-Pacific rose 8% on 5% higher volumes, according to the company's 29 October 2026 release.
- Contracted work keeps growing. The 10-Q filed 29 October 2026 shows a backlog of $66,000 million at 30 September 2026, up 6.5% from a year earlier, and the release cites a $7.9 billion contractual sale-of-gas project backlog.
- Cash funds buybacks and dividends. Operating cash flow was $10,710 million over the four quarters to 30 September 2026 and free cash flow $5,080 million (10-Q). The diluted share count fell 1.9% from a year earlier, and the company returned $1,685 million to shareholders in the third quarter.
- Analysts lifted targets after the report. Goldman Sachs raised its target to $595 on 2 November 2026, Barclays to $591 and Citi to $580 on 30 October 2026, and RBC Capital to $568 on 30 October 2026.
- Lincare actions could lift margins. Lincare has weighed on margins since the second quarter of 2026, as Lamba said on the 31 July 2026 call. A sale or restructuring would remove that drag. The company said fourth-quarter guidance assumes no meaningful profit improvement there.
Bear case
- Growth slows in the guidance. Fourth-quarter adjusted EPS guidance of $4.40–4.50 implies 5%–7% growth, against 9% in the third quarter, with no currency help assumed (29 October 2026 release).
- Gross margin has slid five quarters running. Filed gross margin fell from 49.3% in the quarter to 30 June 2025 to 47.2% in the quarter to 30 September 2026. Reported operating margin was 22.9% in the latest quarter, against 27.5% in the June quarter, after the charge.
- Europe is barely growing. Europe, Middle East and Africa underlying sales rose 3% in the third quarter, with volumes up only 1% (29 October 2026 release).
- The project pipeline has stopped expanding. The sale-of-gas backlog stood at a record $8.1 billion after the 31 July 2026 second-quarter report, and $7.9 billion with the third-quarter report. The company expected it to end 2026 near $8 billion as more than 20 projects start up.
- Executives sold after option exercises. SEC Form 4 filings show the chief financial officer sold 86,833 shares at an average of $521.21 on 4 November 2026 after exercising 228,175 options. The chief legal officer sold 9,350 shares at $518.91 on 2 November 2026.
- Not every target moved up. BMO cut its target to $540 from $546 on 3 November 2026, and Equita's raised target of $520 on 2 November 2026 sits below the 13 November 2026 close.
Price setup
Linde closed at $526.06 on 13 November 2026. The 52-week intraday high is $548.20, set on 7 July 2026, and the last close is 4.0% below it. The 52-week closing low is $389.38, set on 8 December 2025.
The shares sit above both the 50-day moving average of $490.2 and the 200-day moving average of $494.57, as of the 13 November 2026 close. The 50-day average is still below the 200-day, so the recovery from late summer is recent. The three-month change is 11.3%, measured from a close of $474.33 on 17 August 2026.
In the week after the report the shares held a narrow range. They closed at $515.25 on 6 November 2026 and between $520.33 and $526.55 from 9 November to 13 November 2026. The July high is the level the price has to clear to show leadership.
Catalysts ahead
- ~1 December 2026 (est.): ISM manufacturing index for November 2026. US factory activity drives Americas gas volumes, which rose only 3% in the third quarter; a sharp change would move expectations for 2027 volume growth.
- ~5 February 2027 (est.): Fourth-quarter 2026 report and 2027 outlook. It shows whether adjusted EPS lands in the $4.40–4.50 guide and whether 2027 guidance holds growth near the 8%–9% of 2026. It may also update the Lincare review.
What would change the view
A daily close above $549, which would put the shares above their July 2026 52-week high and show them leading, or a 2027 adjusted EPS outlook above the 8%–9% growth guided for 2026.
What it trades with
Linde's results depend on industrial production in the Americas, Europe and Asia, on electronics demand, and on pricing in long-term gas contracts. Its closest US-listed peer is Air Products (APD). AdaptHealth (AHCO) competes with Lincare in US home respiratory care. A common market view is that large, low-volatility industrial-gas stocks trade as defensive holdings, so they hold up in index sell-offs and trail in strong rallies. The company issued two euro bond tranches of €650 million each on 12 November 2026, against debt of $26,702 million at 30 September 2026. That adds to its exposure to European rates and the euro, which the company assumed gave a 2% currency benefit to full-year 2026 EPS.
The evidence, claim by claim (8)
- Third-quarter 2026 sales were $9,404 million, up 9% from a year earlier, with underlying sales up 5%; adjusted operating margin was 29.4%. Linde third-quarter 2026 earnings release, Form 8-K exhibit 99.1 · as of
- Third-quarter adjusted EPS was $4.59, up 9%; reported EPS was $3.66, down 11%. Linde third-quarter 2026 earnings release, Form 8-K exhibit 99.1 · as of
- Full-year 2026 adjusted EPS guidance is $17.82–17.92, against $17.70–17.90 given on 31 July 2026; fourth-quarter guidance is $4.40–4.50, up 5%–7%. Linde third-quarter 2026 earnings release · as of
- A $425 million charge was split roughly half to severance in lower-growth regions, with most of the rest going to portfolio and asset actions at Lincare. Linde third-quarter 2026 earnings call · as of
- Gross margin fell to 47.2% in the quarter to 30 September 2026, from 49.3% in the quarter to 30 June 2025. Linde 10-Q filings · as of
- Backlog stood at $66,000 million at 30 September 2026, up 6.5% from a year earlier; debt was $26,702 million. Linde third-quarter 2026 10-Q · as of
- The chief financial officer exercised 228,175 options and sold 86,833 shares on the open market at an average of $521.21. SEC Form 4 filed 6 November 2026 · as of
- Goldman Sachs raised its Linde target to $595 from $580; BMO cut its target to $540 from $546 on 3 November 2026. Goldman Sachs and BMO research notes, as reported by fiscal.ai · as of
Sources
- LINDE PLC - Form 8-K - FY2026 · sec.gov
- Zacks
- LINDE PLC - Form 10-Q - FY2026 · sec.gov
- Linde Q2 Earnings Call Highlights · marketbeat.com ·